Figure 1.
Rosiglitazone protects C57BL/6J mice from ANIT‐induced intrahepatic cholestasis by activating bile homeostatic proteins and production of 15d‐PGJ2, while reducing Nogo. (a) (The schedule of treatment): C57BL/6J mice were randomly divided into four groups (eight per group) and received intragastric administration of corn oil (Vehicle), rosiglitazone (Rosi, 30 mg·day−1·kg−1), ANIT (80 mg·kg−1) once on Day 4, or ANIT plus Rosi as indicated. Two days after ANIT treatment, mouse tissue samples were collected. (b) Representative photographs of liver and serum samples from each group. (c) Liver paraffin sections were stained with H&E. (d) Expression of ABCB4, ABCG5, BSEP, CYP7A1, FXR was determined as total protein extracted from liver. (e) PPARγ protein was determined by western blot with quantification of band density. * ^ P < .05, significantly different from Vehicle group, n = 6. (f, g) Levels of 15d‐PGJ2 and Nogo were determined in serum samples using ELISA assay kits. n = 6 for Vehicle and Rosi groups, n = 7 for ANIT and ANIT + Rosi groups. * P < .05, significantly different as indicated